PRODUCT

Vesugen (Lys-Glu-Asp) (20 mg Vial)

No short description available.

Quickstart Highlights

Vesugen (Lys-Glu-Asp, also known as KED) is a tripeptide bioregulator synthesized at the Saint Petersburg Institute of Bioregulation and Gerontology[1]. Research suggests it may support vascular endothelial cell proliferation through epigenetic regulation of Ki-67 gene expression[2]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
Typical daily range: 500–2000 mcg once daily (gradual titration).
Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Reconstitution

Draw 3.0 mL bacteriostatic water with a sterile syringe [9] .
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light [10] .
Draw 3.0 mL bacteriostatic water with a sterile syringe[9].
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light[10].

Protocol Overview

Goal:Support vascular endothelial function and cellular renewal over time[2].
Schedule:Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range:500–2000 mcg daily with gradual titration.
Reconstitution:3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
Storage:Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosage Protocols

Start:500 mcg daily; increase by ~500 mcg weekly as tolerated.
Target:1500–2000 mcg daily by Weeks 3–8+.
Frequency:Once per day (subcutaneous).
Cycle Length:8–12 weeks; optional extension to 16 weeks.
Timing:Any consistent time; rotate injection sites.

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[12].
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.

How It Works

Vesugen (KED) is a tripeptide derived from amino acids associated with vascular wall proteins[1]. Research indicates it may support vascular endothelial cell proliferation by modulating the expression of Ki-67, a protein closely associated with cell division[2]. The peptide is hypothesized to interact with promoter regions of the Ki-67 gene, potentially influencing epigenetic regulation[3]. Additional studies suggest Vesugen may normalize endothelin-1 expression and increase sirtuin-1 (SIRT-1) expression in vascular endothelial cells[4].

Lifestyle Factors

Pair with a balanced, heart-healthy diet rich in antioxidants and omega-3 fatty acids.
Combine regular cardiovascular exercise to reinforce vascular adaptations.
Prioritize sleep and stress management to support recovery and cellular renewal.

Injection Technique

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[11][12].
Do not aspirate for subcutaneous injections; inject slowly and steadily[11].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[12].

Benefits and Side Effects

Benefits

May support vascular endothelial cell proliferation and renewal through Ki-67 gene regulation[2][3].
Research suggests potential neuroprotective properties; oral application improved memory and attention in elderly individuals with functional CNS disorders[5].
May restore synaptic plasticity in in vitro models of Alzheimer’s disease[6].

Side Effects

Generally well tolerated in reported studies; occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.

Vesugen (Lys-Glu-Asp) (20 mg Vial)

Resources

Categories

Company